By Dr. Seronei C. Cheison, Sinonin Biotech | 21 May 2026 | 9 min read
Interzoo 2026 (Nuremberg, 12–15 May) drew approximately 2,400 exhibitors from ~70 countries across 150,000 m² — and unveiled an unusual concentration of alternative-protein commercial launches. Photo: Thomas Geiger / WZF, via petfoodindustry.com.
Between 7 and 16 May 2026, five commercial milestones in the United States, the United Kingdom and continental Europe pushed alternative proteins from a sustainability side-conversation to a named, dated commercial product category inside the USD 140 billion global pet-food market. Mycoprotein, cultivated meat, precision-fermentation animal protein, and algal omega-3 all booked first-of-kind commercial events inside a single ten-day window centred on Interzoo 2026, the world’s largest pet-industry trade fair. Here is what happened, why it happened in that order, and what I think it means for the future of protein production well beyond pets.
Key Highlights
- Five alternative-protein commercial milestones occurred within ten days in May 2026: an FDA Letter of No Objection for precision-fermentation lamb protein (Bond Pet Foods × Hill’s Pet Nutrition); the European launch of the first complete-and-balanced cultivated-meat dog food (FORZA10 × BeneMeat “Coolty Meat”); the first commercial mycoprotein petfood product (Enifer × Rovio Pet Foods, PEKILO®); the inaugural Interzoo Sustainability Award for algal omega-3 (dsm-firmenich); and Meatly’s £10.4 M Series A for a 20,000-litre cultivated-meat pilot facility in London.
- Coolty Meat is a complete-and-balanced dog food at 26 % cultivated meat inclusion, classified as a hypoallergenic mono-protein dietetic diet under EU PARNUT legislation. That is a step-change from the 4 % cultivated-chicken inclusion in Meatly’s UK treats launch only fifteen months earlier.
- The BeneMeat “Try & Share” consumer programme — ~350 dog–owner dyads across 25 European countries (Sept–Dec 2025) — reported ~88 % “dogs liked it”, ~85 % “visibly excited” and ~83 % “as good as or better than what they normally eat”, to my knowledge the largest published consumer dataset for cultivated petfood.
- Three controlled in-vivo studies published in 2024–2026 (Linde et al. on 12-month canine plant-based diets; Mioto et al. on defatted black-soldier-fly meal at 0/7.5/15 % chicken replacement; Enifer’s 60-day PEKILO® trial) substantially close the long-standing evidence gap that had held adoption back.
The week that changed pet food
I have argued in long form — most recently in a peer-reviewed perspective with my co-author Raluca-Ioana Alexa — that pet nutrition is the lead translational market for the next generation of protein technologies: the regulatory environment is more flexible than human food, pet owners pay a premium for innovation, and the sensory bar imposed by carnivorous species forces real engineering rather than greenwashing. Interzoo 2026 made the same case in compressed form.
The cluster is not coincidence. It reflects technology pipelines that matured at the same time, regulatory frameworks in the US, UK, EU and Asia-Pacific that quietly aligned through 2024–2025, and a deliberate strategic choice by the technology developers themselves to launch into petfood first.
The trade fair itself was the largest edition on record: 2,400 exhibitors from approximately seventy countries, 150,000 square metres of exhibition space, 87 % international participation. Sustainability and alternative proteins ran as dominant themes through both the main programme and the pre-event Petfood Forum Europe and the inaugural Interzoo Sustainability Conference held on 11 May. But the substance was in the five commercial events.
What happened at Interzoo
Coolty Meat — the first complete-and-balanced commercial cultivated-meat dog food, debuted at Interzoo 2026 on 12 May. Image: via petfoodindustry.com.
Coolty Meat: cultivated meat hits 26 % inclusion
The most visible launch was Coolty Meat, debuted on 12 May 2026 by the Italian brand FORZA10 (Nasta Pet Food group, Trento) with the Czech cultivated-meat developer Bene Meat Technologies. Both companies describe it as the world’s first commercial complete-and-balanced cultivated-meat petfood product — distinguishing it from cultivated treats already on the market.
The formulation is a wet dog food with 26 % cultivated meat from rodent (murine) cells, integrated with plant carriers, supplemented to AAFCO-comparable nutritional adequacy, and free of antibiotics, hormones and preservatives. It is sold as a hypoallergenic mono-protein dietetic diet under European PARNUT (Particular Nutritional Use) legislation, with a recommended three-to-eight-week initial feeding period under veterinary supervision. Retail is planned for Q3 2026.
Two design choices are worth dwelling on. The choice of rodent cells rather than bovine, porcine or avian was made by BeneMeat principally on technical grounds — amino-acid profile, suspension-culture characteristics, and a non-allergenic positioning that supports the dietetic indication — not for novelty value. And the 26 % inclusion is materially higher than the 4 % cultivated chicken in the Meatly × THE PACK “Chick Bites” treats launched in the UK in February 2025. A 26 % inclusion at competitive cost lands inside the 25–35 % meat-meal range typical of conventional wet diets. That is the difference between a proof-of-concept and a replacement ingredient.
Internal palatability testing returned a 9/10 acceptance rate, 10/10 long-term preference, and 9/10 overall palatability across the tested cohort. But the more interesting data came from BeneMeat’s “Try & Share” programme: ~350 dog owners in 25 European countries took the cultivated treats home between September and December 2025. ~88 % of owners reported their dogs liked them, ~85 % reported visible excitement, ~83 % rated them as good as or better than the products they normally feed. These are consumer-survey figures, not controlled-trial data — but to my knowledge they constitute the largest published consumer-acceptance dataset for cultivated petfood, by a wide margin.
A 26 % cultivated-meat inclusion at competitive cost is not a treat-format demonstration. It is, in principle, an ingredient-replacement event.
PEKILO® arrives commercially: mycoprotein in pet food
Enifer’s PEKILO® mycoprotein — produced by biomass fermentation of Paecilomyces variotii on agro-industrial side-streams — launched in a semi-moist dog treat with Rovio Pet Foods at Interzoo 2026. Image: via LinkedIn.
On the same day, the Finnish biotech Enifer Oy and Finnish manufacturer Rovio Pet Foods unveiled a semi-moist dog treat formulated with Enifer’s PEKILO® mycoprotein. PEKILO® is produced by biomass fermentation of the filamentous fungus Paecilomyces variotii on agro-industrial side-streams. It delivers more than 60 % protein by dry weight, with an amino-acid profile that approximates animal meat-meal patterns, and contributes functional fibre — β-glucan and chitin — consistent with glycaemic moderation and satiety properties characterised across the broader biomass-fungal literature.
The launch followed Enifer’s first 4-tonne commercial production run in March 2026 and a US FDA GRAS dossier filing the same month, building on prior self-affirmed GRAS status. Enifer’s internal 60-day study in sixteen adult dogs returned high apparent digestibility, no adverse stool effects, and biomarker shifts consistent with immune activation and improved oxidative balance — and palatability strong enough to anchor the semi-moist treat format.
What it means commercially is straightforward. Enifer’s €33 million biomass-fermentation facility in Kantvik, Finland — entering operation in the second half of 2026 with ~3,000 t/yr nameplate capacity — now moves from a pipeline asset to one with secured offtake against a launched product. The downstream partnerships already confirmed — Skretting (aquafeed), Nestlé Purina (petfood), Valio (dairy) — suggest the same pattern will repeat in adjacent sectors over 2026–2028.
Industry endorsement of algal omega-3: dsm-firmenich wins the inaugural Sustainability Award
On 11 May, the eve of the trade fair, dsm-firmenich received the inaugural Interzoo Sustainability Award for the development of algae-based omega-3 ingredients positioned as an alternative to marine fish oil. The winner was selected from 28 submissions by a combined audience-and-jury vote at the Interzoo Sustainability Conference; the other finalists were i Tail Corporation and ADM. Elliott Harris, former United Nations Chief Economist and Assistant Secretary-General for Economic Development, presented the trophy.
Trade-fair awards are partly promotional, but two things make this one significant. The selection criterion was credible substitution of marine fish oil at industrial volumes, not future potential. And the seniority of the jury — combined with the rigour of the brief — reads as mainstream-industry endorsement that algal omega-3 has now moved from a niche premium category to a credible, scale-competitive substitution route across mid-tier and premium petfood.
That signal was reinforced by the parallel announcement that MiAlgae (Edinburgh, UK) had commissioned its Grangemouth scale-up facility in early Q2 2026. The Scottish plant will increase DHA output more than tenfold, recycle ~36.1 million litres per year of Scotch whisky industry by-products as heterotrophic feedstock, and is backed by up to £3 million of joint UK and Scottish government investment. MiAlgae’s commercial supply agreement with Butternut Box (London) for fresh refrigerated dog food, signed in March, lands the algal omega-3 substitution story squarely in the premium mainstream rather than the experimental fringe.
The bracketing milestones outside Nuremberg
On 12 May 2026 the FDA Center for Veterinary Medicine issued a Letter of No Objection on Bond Pet Foods’ GRAS Notice for Lamb Protein Yeast — the first precision-fermentation animal protein cleared for use in US dog food. Image: via feedandadditive.com.
Bond × Hill’s: the FDA’s first precision-fermentation green light
Two further events of comparable weight bracketed Interzoo. On 12 May 2026 — the opening day of the trade fair — the FDA Center for Veterinary Medicine issued a Letter of No Objection on the GRAS Notice for Lamb Protein Yeast, a precision-fermentation-derived animal protein developed jointly by Bond Pet Foods (Boulder, CO) and Hill’s Pet Nutrition (Topeka, KS, Colgate-Palmolive). The clearance supports use at up to 15 % of finished food in healthy adult dogs, supported by a six-month longitudinal feeding study at the University of Illinois Urbana-Champaign.
This is the first precision-fermentation-derived animal protein cleared via the FDA GRAS-Notice route for US dog food. It establishes a procedural precedent that other notifiers with engineered-yeast and engineered-bacterial platforms — Calysta, KnipBio, Enifer and others — can be expected to invoke. Bond and Hill’s have already signalled that a feline submission is in preparation.
Meatly Series A: capital backs the cultivated-meat infrastructure
Five days earlier, on 7 May 2026, Meatly (London) closed a £10.4 million Series A funding round to construct a 20,000-litre cultivated-meat pilot facility — what the company describes as Europe’s largest cultivated-meat production site. The cost trajectory the company disclosed is, in my view, the most important quantitative datapoint of the entire ten-day window: chemically defined, protein-free growth medium fell from ~£1 per litre in 2024 to £0.22 per litre in 2025, against an industrial-scale target of £0.015 per litre. The pilot-scale 320-litre bioreactor was built for ~£12,500. Stainless-steel incumbents at comparable working volume run an order of magnitude higher.
Together, Bond × Hill’s and Meatly bookend a four-day window in which the regulatory, commercial-launch and capital-formation dimensions of cell-derived alternative proteins in petfood all advanced materially.
Why this isn’t just five news stories
Petfood is now the lead translational market for the next protein wave. The Interzoo 2026 cluster is the most concentrated evidence to date for that proposition.
Three reasons I read the cluster as a structural inflection rather than a series of coincidences.
First, the market is now too large to ignore. Pet food alone has expanded at >6 % per year since 2020, with the global pet-care category now over EUR 189 billion when services are included — an addressable market for alternative-protein ingredients in the low tens of USD billions by 2030 at even single-digit inclusion levels. North America accounts for roughly EUR 84.6 B, Europe EUR 52.4 B; the rest sits in Asia-Pacific and Latin America, both growing fast.
Second, the evidence base has caught up. Three controlled in-vivo studies published in 2024–2026 — Linde et al. (12-month plant-based diet in 15 dogs, all clinical parameters within reference range), Mioto et al. (BSFL at 0/7.5/15 % chicken replacement, no adverse markers, palatability parity), and the Enifer 60-day PEKILO® trial — close the controlled-trial evidence gap that had held adoption back. Combined with the BeneMeat Try & Share consumer dataset, what was previously dismissed as enthusiast advocacy now sits on a measured, dated, citable evidence base.
Third, regulators across four jurisdictions are now visibly aligning. The US has Bond × Hill’s GRAS precedent plus AAFCO BSFL (2021) and defatted mealworm (2024). The EU maintains BSFL, mealworm, mycoprotein and microalgae in its Feed Materials Catalogue, just authorised UV-treated Tenebrio molitor powder for human consumption (Reg. (EU) 2025/89, 20 January 2025), and accepts BeneMeat (2023) and BioCraft (2024) petfood notifications. The UK FSA published in January 2026 the world’s first dedicated guidance on cell-cultivated foods for human consumption. Singapore granted Asia’s first cultivated petfood approval in June 2025 and cultivated duck approval (Parima) in April 2026.
The persisting Italian prohibition on cultivated meat is real but does not at present block the European-level petfood pathway, because cultivated petfood is regulated under the EU feed-materials and feed-additives framework rather than as a novel food.
Business lessons: who broke, what works
Two business models, one sector inflection: the B2B ingredient-supply + brand-partnership pattern of the May 2026 winners (top) against the vertical-integration pattern that broke in 2025 (bottom). Diagram by author.
The May 2026 cluster lands against a much less benign capital backdrop than 2021–2023.
Ÿnsect — once Europe’s flagship insect-protein scale-up — was placed in judicial liquidation by a French commercial court in December 2025 after restructuring attempts failed. The flagship Dole facility is being wound down; a smaller pilot continues as an insect-fertiliser venture. Ÿnsect had raised in excess of EUR 600 million. Earlier in 2025, Wild Earth — the US plant-based petfood brand — entered Chapter 11 restructuring.
Both episodes have become canonical cautionary cases against highly capital-intensive, vertically integrated business models that try to scale production and create a consumer brand simultaneously while subsidies and headline funding rounds substitute for working revenue.
The five May 2026 winners offer the textbook contrast. Bond Pet Foods, BeneMeat, Enifer, dsm-firmenich and Meatly all operate principally as ingredient or technology suppliers to established petfood brands rather than as vertically integrated branded businesses. Bond supplies Hill’s. BeneMeat supplies FORZA10. Enifer supplies Rovio, Skretting, Nestlé Purina and Valio. Meatly’s 2025 launch was through THE PACK, with Pets at Home as retail partner.
The investor-screening question now widely discussed in the sector — “is this business a brand pretending to be a technology company, or a technology company executing a focused brand strategy?” — has acquired sharp practical force.
A second pattern is worth flagging. Magic Valley, the Melbourne cultivated-meat developer that launched the “Rogue Pet” cultivated-pork dog-treat brand in Australia in March 2026, positions its petfood programme explicitly as an early-revenue and learning channel that funds a longer-range human-food cultivated-meat objective. Petfood is the on-ramp, not the destination. I expect this pattern to recur across the cultivated and precision-fermentation segments over 2026–2028 as more developers face the same lead-translational-market choice.
What’s next: 2026–2030
Three predictions follow.
One. The 2026–2028 window will see a succession of further commercial firsts in cultivated and precision-fermentation petfood: feline cultivated-meat products (BeneMeat, BioCraft Pet Nutrition); cultivated-seafood cat products (Friends & Family / Umami Bioworks across Singapore, the UK and EU); a feline FDA clearance for Bond and Hill’s; commercial cultivated chicken and turkey ingredients in US dog food via further GRAS-Notice precedents; and likely an inaugural EU petfood-specific cultivated-meat authorisation under the feed-additives or feed-materials framework.
Two. Cultivated and precision-fermentation ingredients will begin to displace mainstream meat-meal inclusion at the 5–15 % level in mid-tier dry petfood, not merely at the 1–5 % level in premium or therapeutic formats. The Coolty Meat 26 % inclusion in a complete-and-balanced wet diet is the immediate proof point.
Three. The cumulative pet-channel data — controlled studies, consumer-acceptance datasets, real-world post-market surveillance — will be the principal input into the parallel human-food regulatory dossiers being prepared by the same technology developers. Petfood will continue to serve as the translational learning ground, with measurable lead times.
Three risks bound the optimism. Financing-cycle exposure remains the dominant sectoral risk. Cell-line provenance and welfare considerations for cultivated meat (especially the use of rodent or other non-traditional cells) will become a higher-salience consumer-communication challenge as inclusion levels rise. And the EU human-food cultivated-meat framework — currently working through national positions, including the Italian ban — will continue to set the political backdrop against which petfood operates.
The bottom line
Between 7 and 16 May 2026, alternative proteins crossed the commercial threshold in pet nutrition. Mycelial, cell-cultivated, microalgal and precision-fermentation proteins are no longer pipeline assets — they are ingredient categories with named, dated commercial product launches addressing a USD 140-plus billion market. Petfood is now the lead translational market for the next protein wave, ahead of aquaculture and well ahead of human food.
The most resilient operating models are B2B ingredient suppliers partnered with established petfood brands, not vertically integrated standalone consumer brands. The cautionary cases that have become canonical — Ÿnsect, Wild Earth — make that screening question concrete.
I expect the next 24–36 months to deliver more of the same: faster, denser clusters of commercial firsts, increasingly cross-jurisdictional, increasingly mid-tier rather than only premium. Interzoo 2026 was the inflection point. The work now is in the execution.
About the author. Dr. rer. nat. habil. Dr. Seronei Chelulei Cheison is the founder and CEO of Sinonin Biotech GmbH (Langwedel, Germany). He holds a Habilitation with Venia Legendi in Food Biotechnology from the Technical University of Munich (TUM) and brings more than twenty years of international experience across food science, dairy and protein biotechnology, and pet nutrition and petfood palatability — including senior roles in the petfood industry prior to founding Sinonin Biotech. His current work focuses on alternative-protein ingredients and translational strategy across pet nutrition and petfood palatant innovation and adjacent markets. He writes on alternative protein themes in the petfood space and serves on the industry Advisory Board of the Protein Production Technology.
Cite this post: Cheison, S. C. (2026). Five milestones, ten days, one $140 billion market: lessons from Interzoo 2026. Sinonin Biotech blog, 21 May 2026.
